NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
20 trialsNCT04550494 2026-04-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06184750 2026-04-13
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05557877 2026-03-31
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT03941730 2026-03-05
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT06860815 2026-01-28
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02849496 2025-11-24
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04529044 2025-10-30
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT01149083 2025-08-15
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT00499083 2023-09-29
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Phase 2 Completed
NCT05619016 2022-11-30
[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors
Karolinska University Hospital
Phase 2 Unknown
NCT02997995 2020-09-30
ULTIMATE
UNICANCER
Phase 2 Completed
NCT01372579 2019-06-07
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Northwestern University
Phase 2 Unknown
NCT00847171 2018-09-26
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00088829 2018-07-11
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
Georgetown University
Phase 2 Terminated
NCT00201773 2015-06-30
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00343512 2012-04-27
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00645866 2011-05-16
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer
Mayo Clinic
Phase 2 Completed